US20020042391A1 - Gemcitabine derivatives - Google Patents
Gemcitabine derivatives Download PDFInfo
- Publication number
- US20020042391A1 US20020042391A1 US09/355,112 US35511299A US2002042391A1 US 20020042391 A1 US20020042391 A1 US 20020042391A1 US 35511299 A US35511299 A US 35511299A US 2002042391 A1 US2002042391 A1 US 2002042391A1
- Authority
- US
- United States
- Prior art keywords
- gemcitabine
- ester
- elaidic
- amide
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *[Y].*[Y]*.C.C Chemical compound *[Y].*[Y]*.C.C 0.000 description 2
- QGIVVUHGTUTZPD-UHFFFAOYSA-N CNC1=NC(=O)N(C2OC(COC)C(OC)C2(F)F)C=C1 Chemical compound CNC1=NC(=O)N(C2OC(COC)C(OC)C2(F)F)C=C1 QGIVVUHGTUTZPD-UHFFFAOYSA-N 0.000 description 2
- SDUQYLNIPVEERB-UHFFFAOYSA-N NC1=NC(=O)N(C2OC(CO)C(O)C2(F)F)C=C1 Chemical compound NC1=NC(=O)N(C2OC(CO)C(O)C2(F)F)C=C1 SDUQYLNIPVEERB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Definitions
- This invention relates to certain long chain saturated and monounsaturated fatty acid derivatives of 2′,2′-difluoro-deoxycytidine (Gemcitabine), and to pharmaceutical compositions containing them.
- Gemcitabine has the formula:
- Gemcitabine is a nucleoside analogue which has shown effect for the treatment of neoplastic conditions in both in vitro and in in vivo studies.
- New anticancer agents Weiss et al, Cancer Chemotherapy and Biological Response Modifiers Annual 16, editors Pinedo, Longo and Chabner, 1996. Elsevier Science B. V., Supplement to Seminars in Oncology, Vol. 22, No. 4, Suppl. 11, 1995, editors Yarbro et al. Gencitabine Hydrochloride: Status of Preclinical Studies).
- a beneficial effect has also been observed in the clinical development of Gemcitabine. In these studies both the clinical and side effects of Gemcitabine are highly schedule dependent. (Seminars in Oncology, Vol. 22, No. 41 Suppl. 11, 1995, pp 42-46).
- Gencitabine is activated inside the cell by deoxycytidine kinase to its active form, the triphosphate of Gemcitabine (dFdCTP). Parallel to this Gemcitabine is deactivated by deoxycytidine deaminase to the corresponding uracil derivative (inactive).
- R 1 , R 2 and R 3 are independently selected from hydrogen and C 18 - and C 20 - saturated and monounsaturated acyl groups, with the proviso that R 1 , R 2 and R 3 cannot all be hydrogen.
- Gemcitabine has three derivatisable functions, namely the 5′- and 3′-hydroxyl groups and the N 4 ⁇ amino group. Each group can selectively be transformed into an ester or amide derivative, but di-adducts (di-esters or ester-amides) and tri-adducts may be formed as well. In the case of the di- and tri-adducts the acyl substituent groups need not necessarily be the same.
- the mono-acyl derivatives of this invention i.e. with two of R 1 , R 2 and R 3 being hydrogen, are preferred. It is especially preferred that the monosubstitution with the acyl group should be in the 3′-O and 5′-O positions of the sugar moiety, with 5′-O substitution being most preferred.
- the double bond of the mono-unsaturated acyl groups may be in either the cis or the trans configuration, although the therapeutic effect may differ depending on which configuration is used.
- the position of the double bond in the monounsaturated acyl groups also seem to affect the activity.
- esters or amides having their unsaturation in the ⁇ -9 position.
- the position ⁇ of the double bond of a monounsaturated fatty acid is counted from the terminal methyl group, so that, for example, eicosenoic acid (C 20 :1 ⁇ -9) has 20 carbon atoms in the chain and a single double bond is formed between carbon 9 and 10 counting from the methyl end of the chain.
- Esters, ester-amides and amides of Gemcitabine derived from stearic acid (C 18 :0) and eicosanoic acid (C 20 :0) are advantageously used in some cases.
- Nu-YH stands for Gemcitabine
- Y is oxygen at the 3′ and/or 5′ position of the sugar moiety or nitrogen at the 4 position of the pyrimidine moiety of Gemcitabine
- Fa is an acyl group of a monounsaturated C 18 or C 20 fatty acid
- X is a leaving group, for example Cl, Br, 3-thiazolidine-2-thione or OR′ wherein R′ is Fa, COCH 3 , COEt or COCF 3 .
- a proton scavenger needs to be present in order to mop up the acid HX which is liberated by the reaction.
- a base may be added to the reaction mixture.
- a tertiary amine base such as triethylamine, N,N-dimethylaniline, pyridine or N,N-dimethylaminopyridine can be added to the reaction mixture to bind the liberated hydrohalic acid.
- a solvent used in the reaction may serve as the proton scavenger.
- the reactive fatty acid derivative FaX may, in some cases, be formed in situ by means of coupling reagents such as N,N′-dicyclohexylcarbodiimide (DCC), N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide (EDC) or O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU).
- DCC N,N′-dicyclohexylcarbodiimide
- EDC N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide
- TBTU O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate
- the reactions are preferably carried out in an unreactive solvent such as N,N-dimethylformamide or a halogenated hydrocarbon, such as dichloromethane. If desired any of the above mentioned tertiary amine bases may be used as solvent, taking care that a suitable excess is present. In this case a separate proton scavenger is not needed.
- the reaction should preferably be kept between 5° C. and 5° C. After a period of 1 to 60 hours, the reaction will be essentially completed. The progress of the reaction can be followed using thin layer chromatography (TLC) and appropriate solvent systems. When the reaction is completed as determined by TLC, the product can be extracted with an organic solvent and purified by chromatography and/or recrystallization from an appropriate solvent system.
- TLC thin layer chromatography
- acylated compounds may be produced. If required, the individual mono- and multi-acylated derivatives required may be separated by, for instance, chromatography, crystallization, supercritical extraction, etc.
- Preferred Gemcitabine derivatives of this invention have a higher therapeutic value for treating malignant diseases than Gemcitabine itself. This has been shown in two different in-vivo models with both single and repeated dosing. For single dose treatment, the effect of the derivatives are better or comparable to Gemcitabine. This is especially pronounced for the amide derivative where superior effect is obtained with just 25% of the Gemcitabine dose.
- preferred Gemcitabine derivatives of the invention yield an optimal plasma level of Gemcitabine for a prolonged time without reaching inhibitory concentrations (>35 ⁇ M). This may be because the derivatives are not subject to phosphorylation and probably not an inhibitor of the mechanism either.
- MDR Multi drug resistance
- nucleosides and nucleoside analogues such as gemcitabine
- NT Nucleoside Transport
- Modulation/inhibition of this receptor may be seen as resistance to the drug in a clinical situation. This phenomenon can be observed in-vitro through addition of NT inhibitors. We have surprisingly seen that our derivatives are not influenced by the presence of NT inhibitors, since the cytostatic activity of the preferred derivatives is conserved in the presence of such inhibitors.
- the derivatives of this invention are poor substrates for the deactivating enzyme, and therefore their half-life is increased. Consequently, the derivatives of this invention are more suited than Gemcitabine itself for systemic or local treatment of malignant tumours.
- the new compounds of this invention are not only potentially useful in the treatment of cancer, but also have activity as anti-viral agents.
- the cell lines were the human ovarian tumour line A2780 and subline AG6000 which is resistant to Gemcitabine and has a deficiency of deoxycytidine kinase, and the murine colon tumour line C26A and the subline C26G with no altered deoxycytidine kinase but a 10-fold decrease in thymidine kinase I.
- the cytotoxicity of each compound was evaluated following continuous drug exposure for 72 hours.
- the cell numbers were determined by SRB assay, and percentage growth inhibition was calculated for each tumour line as IC50 value, given in ⁇ M, that is the concentration of the compound giving rise to a 50% growth inhibition compared to control.
- the cytostatic activity of gemcitabine and gemcitabine-5′-elaidic acid ester in CEM cells was determined with and without the nucleoside transport modifiers Nitrobenzylthioinosine (NBMPR) or Persantine (Pyridamole).
- NBMPR Nitrobenzylthioinosine
- Pyridamole Persantine
- the IC 50 gemcitabine is >two-fold higher than the IC 50 gemcitabine-5′-elaidic acid ester.
- NT inhibitors there is a ten-fold rise in the IC 50 gemcitabine values, while the IC 50 gemcitabine-5′-elaidic acid ester is little affected (1.3-1.5 increase).
- the preferred derivative is 15-20 fold more potent then the mother drug.
- mice were inoculated with the murine colon cancer Co-26 in the spleen on day 0. In this model, tumours develop mainly in the liver. Intraperitoneal treatment was started on day 1. Single doses of the compounds were tested in comparison with Gemcitabine at single dose. Saline was used as control. Mean Long survival term No.
- B6D2F1 female mice were implanted with the murine lymphatic leukaemia P 388 cells intraperitoneally. Treatments were initiated on day 1 post implantation of cells intraperitoneally. Mean survival time, long term survivors and toxic deaths were recorded following single dose treatment, repeated dose treatment for 5 days and repeated dose treatment for 10 days. The results are presented in the tables below. Single dose treatment with Gemcitabine-5′-elaidic ester was effective with prolonged survival time and long term survivor observed compared to the same dose of Gemcitabine.
- Treatment for 10 days increased the anti tumour activity compared to shorter treatment.
- Toxicity of Gemcitabine was larger on a mg/kg basis, with ⁇ fraction (6/6) ⁇ toxic deaths at 4 mg/kg.
- Long term survivors were observed post repeated treatment with both Gemcitabine-N 4 - elaidic amide and Gemcitabine-5′-elaidic ester, and substantially increased mean survival times were observed for both Gemcitabine-N 4 - elaidic amide and Gemcitabine-5′-elaidic ester.
- the Gemcitabine esters or amides of the present invention may be administered systemically, either enterally or parenterally.
- the active compounds of the present invention may be presented as, e.g. soft or hard gelatine capsules, tablets, granules, grains or powders, drags, syrups, suspensions or solutions.
- the preparation can contain inert or pharmacodynamically active additives, as well known to those skilled in the formulation arts.
- tablets or granulates can contain a series of binding agents, filler materials, emulsifying agents, carrier substances or dilutes.
- Liquid preparations may be present, for example in the form of a sterile solution.
- Capsules can contain a filler material or thickening agent in addition to the active ingredient. Furthermore, flavour-improving additives as well as the substances usually used as preserving, stabilising, moisture-retaining and emulsifying agents, salts for varying the osmotic pressure, buffers and other additives may also be present.
- the dosage in which the preparations according to this invention are administered will vary according to the mode of use and route of use, as well as to the requirements of the patient.
- a daily dosage for a systemic therapy for an adult average patient will be about 0.1-150 mg/kg body weight/day, preferably 1-40 mg/kg/day.
- an ointment for instance, can contain from 0.1-109% by weight of the pharmaceutical formulation, especially 0.5-5% by weight.
- the pharmaceutical preparation containing the Gemcitabine esters or amides can contain an antioxidant, e.g. tocopherol, N-methyl-tocophermine, butylated hydrocyanisole, ascorbic acid or butylated hydroxytoluene.
- an antioxidant e.g. tocopherol, N-methyl-tocophermine, butylated hydrocyanisole, ascorbic acid or butylated hydroxytoluene.
- Combination therapies i.e. in which the administration of a Gemcitabine ester or amide of this invention is carried out in conjunction with other therapies, e.g. surgery, radiation treatment and chemotherapy, are also contemplated.
- other therapies e.g. surgery, radiation treatment and chemotherapy
- the preferred treatment of brain tumours seems likely to be a combination of surgery and treatment with a Gemcitabine ester or amide of this invention by systemic or local administration.
Abstract
Description
-
- Gemcitabine is a nucleoside analogue which has shown effect for the treatment of neoplastic conditions in both in vitro and in in vivo studies. (New anticancer agents, Weiss et al, Cancer Chemotherapy and Biological Response Modifiers Annual 16, editors Pinedo, Longo and Chabner, 1996. Elsevier Science B. V., Supplement to Seminars in Oncology, Vol. 22, No. 4, Suppl. 11, 1995, editors Yarbro et al. Gencitabine Hydrochloride: Status of Preclinical Studies). A beneficial effect has also been observed in the clinical development of Gemcitabine. In these studies both the clinical and side effects of Gemcitabine are highly schedule dependent. (Seminars in Oncology, Vol. 22, No. 41 Suppl. 11, 1995, pp 42-46).
- Gencitabine is activated inside the cell by deoxycytidine kinase to its active form, the triphosphate of Gemcitabine (dFdCTP). Parallel to this Gemcitabine is deactivated by deoxycytidine deaminase to the corresponding uracil derivative (inactive).
- We have now surprisingly found that certain fatty acid derivatives of Gemcitabine have a totally altered pharmacokinetics and tissue distribution. Especially will this be the case with malignant diseases in the RES, lungs, pancreas, intestines, esophagus, uterus, ovaries, melanoma and mammae.
-
- wherein R1, R2 and R3 are independently selected from hydrogen and C18- and C20- saturated and monounsaturated acyl groups, with the proviso that R1, R2 and R3 cannot all be hydrogen.
- Gemcitabine has three derivatisable functions, namely the 5′- and 3′-hydroxyl groups and the N4− amino group. Each group can selectively be transformed into an ester or amide derivative, but di-adducts (di-esters or ester-amides) and tri-adducts may be formed as well. In the case of the di- and tri-adducts the acyl substituent groups need not necessarily be the same.
- Currently, the mono-acyl derivatives of this invention, i.e. with two of R1, R2 and R3 being hydrogen, are preferred. It is especially preferred that the monosubstitution with the acyl group should be in the 3′-O and 5′-O positions of the sugar moiety, with 5′-O substitution being most preferred.
- The double bond of the mono-unsaturated acyl groups may be in either the cis or the trans configuration, although the therapeutic effect may differ depending on which configuration is used.
- The position of the double bond in the monounsaturated acyl groups also seem to affect the activity. Currently, we prefer to use esters or amides having their unsaturation in theω-9 position. In the ω-system of nomenclature, the position ω of the double bond of a monounsaturated fatty acid is counted from the terminal methyl group, so that, for example, eicosenoic acid (C20:1 ω-9) has 20 carbon atoms in the chain and a single double bond is formed between carbon 9 and 10 counting from the methyl end of the chain. We prefer to use esters, ester-amides and amides derived from oleic acid (C18:1 ω-9, cis), elaidic acid (C18:1 ω-9, trans), eicosenoic acid(s) (C20:1 ω-9, cis) and (C20:1 ω-9, trans), and the amides and 5′-esters are currently the most preferred derivatives of this invention.
- Esters, ester-amides and amides of Gemcitabine derived from stearic acid (C18:0) and eicosanoic acid (C20:0) are advantageously used in some cases.
-
- wherein Nu-YH stands for Gemcitabine, Y is oxygen at the 3′ and/or 5′ position of the sugar moiety or nitrogen at the 4 position of the pyrimidine moiety of Gemcitabine, Fa is an acyl group of a monounsaturated C18 or C20 fatty acid, and X is a leaving group, for example Cl, Br, 3-thiazolidine-2-thione or OR′ wherein R′ is Fa, COCH3, COEt or COCF3. Thus, the reaction proceeds by acylation of the nucleoside. This is accomplished by the use of suitable reactive derivatives of fatty acids, especially acid halides or acid anhydrides.
- Generally, a proton scavenger needs to be present in order to mop up the acid HX which is liberated by the reaction. Thus, a base may be added to the reaction mixture. For example, when an acid halide such as an acid chloride is used, a tertiary amine base, such as triethylamine, N,N-dimethylaniline, pyridine or N,N-dimethylaminopyridine can be added to the reaction mixture to bind the liberated hydrohalic acid. In other cases, a solvent used in the reaction may serve as the proton scavenger.
- Normally, the acylation reaction proceeds without the need for a catalyst. The reactive fatty acid derivative FaX may, in some cases, be formed in situ by means of coupling reagents such as N,N′-dicyclohexylcarbodiimide (DCC), N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide (EDC) or O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU).
- The reactions are preferably carried out in an unreactive solvent such as N,N-dimethylformamide or a halogenated hydrocarbon, such as dichloromethane. If desired any of the above mentioned tertiary amine bases may be used as solvent, taking care that a suitable excess is present. In this case a separate proton scavenger is not needed. The reaction should preferably be kept between 5° C. and 5° C. After a period of 1 to 60 hours, the reaction will be essentially completed. The progress of the reaction can be followed using thin layer chromatography (TLC) and appropriate solvent systems. When the reaction is completed as determined by TLC, the product can be extracted with an organic solvent and purified by chromatography and/or recrystallization from an appropriate solvent system. As more than one hydroxyl group and also an amino group are present in Gemcitabine, a mixture of acylated compounds may be produced. If required, the individual mono- and multi-acylated derivatives required may be separated by, for instance, chromatography, crystallization, supercritical extraction, etc.
- When it is desired to prepare a multi-acyl compound of formula I, in which R1 and/or R2 and/or R3 are the same acyl group, it is preferred to employ the above method(s) using the appropriate acyl-reagent(s) in excess.
-
- The following Examples illustrate the preparation of two preferred Gemcitabine derivatives of this invention.
- Elaidic acid (5′)-Gemcitabine ester
- To a solution of 2′,2′-difluorodeoxyribofuranosylcytosine (Gemcitabine) (0.42 g, 1.6 mmol) in 30 ml DMF was added 0.81 ml DMF containing 1.6 mmol HCl(g) followed by a solution of elaidic acid chloride (0.51 g, 1.7 mmol) in 3 ml DMF and the reaction mixture was stirred at ambient temperature for 12 hours. The solvent was evaporated at high vacuum and the crude product was purified on a column of silica gel with 15% methanol in chloroform as the eluent system. The impure fractions were repurified to give a total of 0.25 g (30%) of the title compound.
-
-
- In addition, a small amount (0.05 g) of the Elaidic acid (3′)-Gemcitabine ester was isolated from impure fractions.
-
-
- Elaidic acid (N4)-Gemcitabine amide
- To a solution of 2′,2′-difluorodeoxyribofuranosylcytosine (Gemcitabine) (0.38 g, 1.3 mmol) in 5 ml pyridine was added elaidic acid chloride (0.57 g, 1.9 mmol) and the reaction mixture was stirred at ambient temperature for 2.5 hours. The solvent was evaporated at high vacuum and the crude product was purified on a column of silica gel with 15% methanol in chloroform as the eluent system. Product containing fractions were evaporated, and the residue was treated with ether/hexan in an ultra-sound bath. The crystalline material was dried to give 0.1 g (15%) of the title compound.
-
-
- Preferred Gemcitabine derivatives of this invention have a higher therapeutic value for treating malignant diseases than Gemcitabine itself. This has been shown in two different in-vivo models with both single and repeated dosing. For single dose treatment, the effect of the derivatives are better or comparable to Gemcitabine. This is especially pronounced for the amide derivative where superior effect is obtained with just 25% of the Gemcitabine dose.
- At repeated dosing, the difference between the derivatives and Gemcitabine is even more striking. This is reflected both in increased survival time and in long term survivors. Another striking feature is the toxicity observed with Gemcitabine itself at both top and mid range repeated dosing. Although the effect obtained with the no-tox-low-range dose (1 mg/kg) is good, it is exceeded by both the N4-amide and the 5′-ester derivatives. Gemcitabine has an optimal effect at a plasma concentration of about 20 μM but higher concentrations, above 35 μM, inhibit the anti-cancer effect due to saturation of the phosphorylation mechanism. (Gandhi, Cellular Pharmacology of Gemcitabine in Gemcitabine: Rationales for Clinical Trial Design and Evaluation, Mini Symposium, 12.3.96, Vrije Universiteit Amsterdam). In contrast, preferred Gemcitabine derivatives of the invention yield an optimal plasma level of Gemcitabine for a prolonged time without reaching inhibitory concentrations (>35 μM). This may be because the derivatives are not subject to phosphorylation and probably not an inhibitor of the mechanism either.
- A main problem in cancer treatment is development of resistance to therapy. Multi drug resistance (MDR) is one of the principal reasons for failure of otherwise effective drugs. We have found that the preferred derivatives of this invention somehow block the MDR-pump, and hence circumvent this problem.
- The cellular uptake of nucleosides and nucleoside analogues such as gemcitabine is mainly via the selective Nucleoside Transport (NT) receptor.
- Modulation/inhibition of this receptor may be seen as resistance to the drug in a clinical situation. This phenomenon can be observed in-vitro through addition of NT inhibitors. We have surprisingly seen that our derivatives are not influenced by the presence of NT inhibitors, since the cytostatic activity of the preferred derivatives is conserved in the presence of such inhibitors.
- The half-life of Gemcitabine in plasma is approximately 10 minutes, due to rapid deamination by the endogenous enzyme deoxycytidine deaminase to the corresponding uracil derivative (P. G. Johnston et al, Cancer Chromatography and Biological Response Modifiers, Annual 16, 1996, Chap. 1, ed. Pinedo H. M. et al.).
- In contrast, the derivatives of this invention are poor substrates for the deactivating enzyme, and therefore their half-life is increased. Consequently, the derivatives of this invention are more suited than Gemcitabine itself for systemic or local treatment of malignant tumours.
- The new compounds of this invention are not only potentially useful in the treatment of cancer, but also have activity as anti-viral agents.
- BIOLOGY
- Experimental
- The cytoxicity activity of Gemcitabine-N4-elaidic amide and Gemcitabine-5′-elaidic ester were investigated in 2 pairs of rodent and human tumour cell lines, each consisting of a parent line and a subline either resistant or cross-resistant to Gemcitabine.
- The cell lines were the human ovarian tumour line A2780 and subline AG6000 which is resistant to Gemcitabine and has a deficiency of deoxycytidine kinase, and the murine colon tumour line C26A and the subline C26G with no altered deoxycytidine kinase but a 10-fold decrease in thymidine kinase I. The cytotoxicity of each compound was evaluated following continuous drug exposure for 72 hours. The cell numbers were determined by SRB assay, and percentage growth inhibition was calculated for each tumour line as IC50 value, given inμM, that is the concentration of the compound giving rise to a 50% growth inhibition compared to control.
- Results
- The IC50 value inμM of cytotoxicity activity of Gemcitabine itself in comparison to cytoxicity activity of Gemcitabine-N4-elaidic amide and Gemcitabine-5′-elaidic ester are shown in the table below. The acitivity of the derivatives of the Gemcitabine is much greater than the cytotoxic activity of Gemcitabine in the cell lines tested.
TABLE The cytotoxicity of Gemcitabine, Gemcitabine-N4- elaidic amide and Gemcitabine-5′-elaidic ester in IC50 (μM) values in the cell lines C26-A, C26-G, A2780 and AG6000 C26-A C26-G A2780 AG6000 Gemcitabine 0.0055 0.0075 0.0005 100 Gemcitabine-N4- <0.0001 <0.0001 <0.0001 35 elaidic amide Gemcitabine-5′- 0.0003 0.0005 <0.0001 100 elaidic ester - The cytostatic activity of gemcitabine and gemcitabine-5′-elaidic acid ester in CEM cells was determined with and without the nucleoside transport modifiers Nitrobenzylthioinosine (NBMPR) or Persantine (Pyridamole). As can be seen from the table below, the IC50 gemcitabine is >two-fold higher than the IC50 gemcitabine-5′-elaidic acid ester. With the addition of NT inhibitors, there is a ten-fold rise in the IC50 gemcitabine values, while the IC50 gemcitabine-5′-elaidic acid ester is little affected (1.3-1.5 increase). In the “resistant” situation, the preferred derivative is 15-20 fold more potent then the mother drug.
IC50 μM IC50 μM No IC50 μM Persantine Compound inhibitor NBMPR 100 μM 4 μg/ml Gemcitabine 0.11 ± 0.01 1.11 ± 0.08 1.26 ± 0.04 Gemcitabine-5′- 0.047 ± 0.006 0.072 ± 0.034 0.065 ± 0.023 elaidic acid ester - The anti tumour effect of Gemcitabine-N4- elaidic amide or Gemcitabine-5′-elaidic ester were investigated in-vivo in mice in two different tumour types, both with single and repeated dosing
- Effect of Gemcitabine-N4- elaidic amide or Gemcitabine-5′-elaidic ester on Co-26 inoculated intrasplenic to mice
- Balb/c female mice were inoculated with the murine colon cancer Co-26 in the spleen on day 0. In this model, tumours develop mainly in the liver. Intraperitoneal treatment was started on day 1. Single doses of the compounds were tested in comparison with Gemcitabine at single dose. Saline was used as control.
Mean Long survival term No. Dose time survivors Toxic Mice Substance mg/kg T/C [%] (>35 d) deaths 10 Saline 8 Gemcitabine- 25 103.7 5/8 1/8 N4- elaidic amide 7 Gemcitabine- 75 128.6 1/7 0/7 5′-elaidic ester 7 Gemcitabine- 100 100.1 4/7 0/7 5′-elaidic ester 7 Gemcitabine 75 132.8 2/7 0/7 7 Gemcitabine 100 116.2 4/7 0/7 - Mean survival time for the animals that died were in the same range for the compounds tested. Gemcitabine-N4-elaidic amide was superior to Gemcitabine-5′-elaidic ester and Gemcitabine with ⅝ survivors at a dose of only 25 mg/kg compared to Gemcitabine at 100 mg/kg.
- In a parallell experiment, dosing was repeated on days 1-11
Mean Long survival term No. Dose time survivors Toxic Mice Substance mg/kg T/C [%] (>46 d) deaths 10 Saline 8 Gemcitabine- 1 155 2/8 0/8 N4- elaidic amide 8 Gemcitabine- 4 185.6 1/8 0/8 N4- elaidic amide 8 Gemcitabine- 1 150.6 1/8 0/8 5′-elaidic ester 8 Gemcitabine- 4 166.9 3/8 2/8 5′-elaidic ester 8 Gemcitabine 1 170.6 2/8 1/8 8 Gemcitabine 4 toxic 0/8 8/8 - In this experiment the results obtained with Gemcitabine-N4-elaidic amide and low dose Gemcitabine-5′-elaidic ester were better or equal to results obtained with the low dose of Gemcitabine. Although the high dose of Gemcitabine-5′-elaidic ester is slightly toxic, it is less so than the high dose of Gemcitabine itself.
- Effect of Gemcitabine-N4-elaidic amide or Gencitabine 5′-elaidic ester on P-388 ip in mice, single doses or repeated doses
- B6D2F1 female mice were implanted with the murine lymphatic leukaemia P 388 cells intraperitoneally. Treatments were initiated on day 1 post implantation of cells intraperitoneally. Mean survival time, long term survivors and toxic deaths were recorded following single dose treatment, repeated dose treatment for 5 days and repeated dose treatment for 10 days. The results are presented in the tables below. Single dose treatment with Gemcitabine-5′-elaidic ester was effective with prolonged survival time and long term survivor observed compared to the same dose of Gemcitabine.
- Single dose treatment
Mean Long survival term No. Dose time survivors Toxic Mice Substance mg/kg T/C [%] (>35 d) deaths 9 Saline 6 Gemcitabine 75 186.3 1/6 0/6 -5′-elaidic ester 6 Gemcitabine 100 138.9 0/6 0/6 -5′-elaidic ester 6 Gemcitabine 75 138.9 0/6 0/7 - Repeated dose treatment, days 1 - 4
ean ong urvival erm No. ose ime urvivors oxic Mice ubstance g/kg /C [%] >35 d) eaths 8 aline 6 emcitabine- 78 /6 /6 4- elaidic mide 6 emcitabine- 83 /6 /6 4- elaidic mide 6 Gemcitabine 5 8.0 /6 /6 - Activity of Gemcitabine-N4- elaidic amide was clear-cut at repeated doses days 1-4 with long term survivors observed and prolonged mean survival time both at 1 and 4 mg/kg. In the control group treated with Gemcitabine at 15 mg/kg all animals died of toxicity.
- Repeated dose treatment, treatment days 1-11
Mean Long survival term No. Dose time survivors Toxic Mice Substance mg/kg T/C [%] (>45 d) deaths 9 Saline 6 Gemcitabine 1 172.5 1/6 0/6 -N4- elaidic amide 6 Gemcitabine 4 215.7 0/6 0/6 -N4- elaidic amide 6 Gemcitabine 1 317.0 0/6 0/6 -5′-elaidic ester 6 Gemcitabine 4 220.6 2/6 0/6 -5′-elaidic ester 6 Gemcitabine 1 178.8 0/6 0/6 6 Gemcitabine 4 71.9 0/6 6/6 - Treatment for 10 days increased the anti tumour activity compared to shorter treatment. Toxicity of Gemcitabine was larger on a mg/kg basis, with {fraction (6/6)} toxic deaths at 4 mg/kg. Long term survivors were observed post repeated treatment with both Gemcitabine-N4- elaidic amide and Gemcitabine-5′-elaidic ester, and substantially increased mean survival times were observed for both Gemcitabine-N4- elaidic amide and Gemcitabine-5′-elaidic ester.
- The Gemcitabine esters or amides of the present invention may be administered systemically, either enterally or parenterally.
- For enteral administration, the active compounds of the present invention may be presented as, e.g. soft or hard gelatine capsules, tablets, granules, grains or powders, drags, syrups, suspensions or solutions.
- When administered parenterally, preparations of the Gemcitabine esters or amides as injection or infusion solutions, suspensions or emulsions are suitable.
- The preparation can contain inert or pharmacodynamically active additives, as well known to those skilled in the formulation arts. For instance, tablets or granulates can contain a series of binding agents, filler materials, emulsifying agents, carrier substances or dilutes. Liquid preparations may be present, for example in the form of a sterile solution.
- Capsules can contain a filler material or thickening agent in addition to the active ingredient. Furthermore, flavour-improving additives as well as the substances usually used as preserving, stabilising, moisture-retaining and emulsifying agents, salts for varying the osmotic pressure, buffers and other additives may also be present.
- The dosage in which the preparations according to this invention are administered will vary according to the mode of use and route of use, as well as to the requirements of the patient. In general a daily dosage for a systemic therapy for an adult average patient will be about 0.1-150 mg/kg body weight/day, preferably 1-40 mg/kg/day. For topical administration, an ointment, for instance, can contain from 0.1-109% by weight of the pharmaceutical formulation, especially 0.5-5% by weight.
- If desired, the pharmaceutical preparation containing the Gemcitabine esters or amides can contain an antioxidant, e.g. tocopherol, N-methyl-tocophermine, butylated hydrocyanisole, ascorbic acid or butylated hydroxytoluene.
- Combination therapies, i.e. in which the administration of a Gemcitabine ester or amide of this invention is carried out in conjunction with other therapies, e.g. surgery, radiation treatment and chemotherapy, are also contemplated. For example, the preferred treatment of brain tumours seems likely to be a combination of surgery and treatment with a Gemcitabine ester or amide of this invention by systemic or local administration.
Claims (12)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9701427 | 1997-01-24 | ||
GB9701427A GB2321454A (en) | 1997-01-24 | 1997-01-24 | Gemcitabine esters and amides |
GB9701427.8 | 1997-01-24 | ||
PCT/NO1998/000020 WO1998032762A1 (en) | 1997-01-24 | 1998-01-23 | Gemcitabine derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020042391A1 true US20020042391A1 (en) | 2002-04-11 |
US6384019B1 US6384019B1 (en) | 2002-05-07 |
Family
ID=26310850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/355,112 Expired - Lifetime US6384019B1 (en) | 1997-01-24 | 1998-01-23 | Gemcitabine derivatives |
Country Status (15)
Country | Link |
---|---|
US (1) | US6384019B1 (en) |
EP (1) | EP0986570B9 (en) |
JP (1) | JP4352115B2 (en) |
KR (1) | KR100483256B1 (en) |
AT (1) | ATE236188T1 (en) |
AU (1) | AU720451B2 (en) |
CA (1) | CA2278056C (en) |
DE (1) | DE69812934T2 (en) |
DK (1) | DK0986570T3 (en) |
HU (1) | HU224918B1 (en) |
NZ (1) | NZ336676A (en) |
PL (1) | PL186888B1 (en) |
SK (1) | SK283879B6 (en) |
UA (1) | UA67736C2 (en) |
WO (1) | WO1998032762A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006090029A1 (en) | 2004-06-30 | 2006-08-31 | Centre National De La Recherche Scientifique | Gemcitabine derivatives nanoparticles |
US20090163564A1 (en) * | 2005-12-28 | 2009-06-25 | Translational Therapeutics, Inc. | Translational Dysfunction Based Therapeutics |
US20090209482A1 (en) * | 2007-09-26 | 2009-08-20 | Mount Sinai School Of Medicine | Azacytidine analogues and uses thereof |
US20110184053A1 (en) * | 2008-05-16 | 2011-07-28 | Centre National De La Recherche Scientifique | Novel nucleic acid transfer system |
WO2013019945A3 (en) * | 2011-08-02 | 2014-05-08 | Clovis Oncology, Inc.. | Method for selection of chemotherapeutic agents for adenocarcinoma cancer |
WO2016057825A1 (en) * | 2014-10-08 | 2016-04-14 | Epigenetics Pharma Llc | Vitamin e-nucleoside prodrugs |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6576636B2 (en) * | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
WO2002076402A2 (en) * | 2001-03-23 | 2002-10-03 | Protarga, Inc. | Fatty amine drug conjugates |
HUP0304093A3 (en) * | 2001-04-06 | 2008-08-28 | Wyeth Corp | Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them |
EP1465615B1 (en) | 2002-01-15 | 2012-08-01 | Trustees of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
AU2003291726A1 (en) | 2002-11-04 | 2004-06-07 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
EP1734972A4 (en) * | 2004-03-29 | 2007-08-22 | Roswell Park Cancer Inst | Method of treating solid tumors and leukemias using combination therapy of vitamin d and anti-metabolic nucleoside analogs |
KR100699099B1 (en) * | 2004-07-29 | 2007-03-22 | 한미약품 주식회사 | 1-?-halo-2,2-difluoro-2-deoxy-d-ribofuranose derivatives and process for the preparation thereof |
WO2006029081A2 (en) * | 2004-09-02 | 2006-03-16 | Neopharm, Inc. | Nucleoside-lipid conjugates, their method of preparation and uses thereof |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
EP1831237B1 (en) * | 2004-12-17 | 2008-08-20 | Eli Lilly And Company | Amide prodrug of gemcitabine, compositions and use thereof |
NO322682B1 (en) * | 2005-03-18 | 2006-11-27 | Clavis Pharma Asa | Use of gemcitabine derivatives for the preparation of oral dosage forms in cancer treatment, as well as such oral dosage forms |
KR100680765B1 (en) * | 2005-04-28 | 2007-02-09 | 주식회사 삼천리제약 | 3'--2'3'- Methods of preparation of 3'-amino-2'3'-dideoxyguanosine |
NO324263B1 (en) * | 2005-12-08 | 2007-09-17 | Clavis Pharma Asa | Chemical compounds, their use in the treatment of cancer, and pharmaceutical compositions comprising such compounds |
JP2009531284A (en) * | 2006-02-06 | 2009-09-03 | ドクター レディズ ラボラトリーズ リミテッド | Preparation of gemcitabine |
TWI417095B (en) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors |
CN101448504B (en) * | 2006-06-21 | 2012-04-11 | 伊莱利利公司 | Crystalline forms of gemcitabine amide prodrug, compositions and use thereof |
US8921340B2 (en) | 2006-11-17 | 2014-12-30 | Trustees Of Dartmouth College | Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions |
WO2008064132A2 (en) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
US7714012B2 (en) | 2006-11-17 | 2010-05-11 | Trustees Of Dartmouth University | Synthesis and biological activities of new tricyclic-bis-enones (TBEs) |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
KR100957756B1 (en) * | 2007-12-12 | 2010-05-12 | 동우신테크 주식회사 | Process for preparing of 2'-deoxy-2'2'-difluorocytidine |
AU2008297876B2 (en) | 2007-09-14 | 2011-07-07 | Addex Pharma S.A. | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
JP5133416B2 (en) | 2007-09-14 | 2013-01-30 | オルソー−マクニール−ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 1 ', 3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H, 1'H- [1,4'] bipyridinyl-2'-one |
DK2082745T3 (en) * | 2007-12-28 | 2013-03-25 | Deutsches Krebsforsch | Cancer therapy with a parvovirus combined with chemotherapy |
RS58486B1 (en) | 2008-01-11 | 2019-04-30 | Reata Pharmaceuticals Inc | Synthetic triterpenoids and methods of use in the treatment of disease |
RS55631B1 (en) | 2008-04-18 | 2017-06-30 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
JP5529851B2 (en) | 2008-04-18 | 2014-06-25 | リアタ ファーマシューティカルズ インコーポレイテッド | Antioxidative inflammation modulator: oleanolic acid derivative with amino modification and other modifications in C-17 |
WO2009146216A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
MX2010011435A (en) | 2008-04-18 | 2011-01-25 | Reata Pharmaceuticals Inc | Compounds including an anti-inflammatory pharmacore and methods of use. |
EP2279197B1 (en) | 2008-04-18 | 2014-11-05 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring |
CA2731650A1 (en) | 2008-07-22 | 2010-01-28 | Tadashi Honda | Monocyclic cyanoenones and methods of use thereof |
EP2344470B1 (en) | 2008-09-02 | 2013-11-06 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
WO2010039039A1 (en) * | 2008-10-03 | 2010-04-08 | Clavis Pharma Asa | Oral formulations of gemcitabine derivatives |
CN102232074B (en) | 2008-11-28 | 2014-12-03 | 奥梅-杨森制药有限公司 | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
CN101525361B (en) | 2009-04-21 | 2010-11-17 | 济南圣鲁金药物技术开发有限公司 | Prodrug based on gemcitabine structure as well as synthesizing method and application thereof |
GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
BRPI1010831A2 (en) | 2009-05-12 | 2016-04-05 | Addex Pharmaceuticals Sa | 1,2,4-triazolo [4,3-a] pyridine derivatives and their as positive allosteric modulators of mglur2 receptors |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
RS53075B (en) | 2009-05-12 | 2014-04-30 | Janssen Pharmaceuticals Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
MX2012005677A (en) * | 2009-11-20 | 2012-08-23 | Clavis Pharma Asa | Parenteral formulations of gemcitabine derivatives. |
GB201006181D0 (en) | 2010-04-14 | 2010-06-02 | Ayanda As | Composition |
PT2649069E (en) | 2010-11-08 | 2015-11-20 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
CA2815002C (en) | 2010-11-08 | 2019-10-22 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
AU2011328195B2 (en) | 2010-11-08 | 2015-04-02 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
US9693957B2 (en) | 2011-07-08 | 2017-07-04 | The University Of North Carolina At Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
CN102432654A (en) * | 2011-09-26 | 2012-05-02 | 宋云龙 | Gemcitabine amide derivates, and preparation method and application thereof |
CN102617679B (en) * | 2012-03-13 | 2014-11-26 | 北京大学 | Preparation method and application of connected conjugated linoleic acid and gemcitabine prodrug |
US9913822B2 (en) | 2012-04-04 | 2018-03-13 | Halozyme, Inc. | Combination therapy with an anti-hyaluronan agent and therapeutic agent |
US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
WO2014040073A1 (en) | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
CN104968353B (en) * | 2012-11-13 | 2017-12-22 | 博研医药开发股份有限公司 | Gemcitabine prodrug and application thereof |
CN103130854A (en) * | 2013-01-31 | 2013-06-05 | 华东师范大学 | Vitamin E succinic acid esterification gemcitabine prodrug and application |
CN103159814B (en) * | 2013-03-28 | 2015-12-23 | 东华大学 | A kind of morellic acid ester derivative and its production and use |
CN103265594B (en) * | 2013-03-28 | 2016-05-04 | 东华大学 | A kind of gambogicacid amide derivatives and its production and use |
JO3368B1 (en) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
JO3367B1 (en) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
WO2015059072A1 (en) * | 2013-10-21 | 2015-04-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of polyomavirus infections |
JP6590802B2 (en) | 2013-11-06 | 2019-10-16 | ザ ユニバーシティ オブ シカゴThe University Of Chicago | Nanoscale transporter for delivery or co-delivery of chemotherapeutic drugs, nucleic acids and photosensitizers |
KR20220051273A (en) | 2014-01-21 | 2022-04-26 | 얀센 파마슈티카 엔.브이. | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
IL279202B2 (en) | 2014-01-21 | 2023-09-01 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
US10463684B2 (en) | 2014-01-29 | 2019-11-05 | Board Of Regents, The Uneversety Of Texas System | Nucleobase analogue derivatives and their applications |
EP3439666A4 (en) | 2016-05-20 | 2019-12-11 | The University of Chicago | Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof |
CN111194232B (en) | 2017-08-02 | 2023-01-31 | 芝加哥大学 | Nanoscale metal-organic layer and metal-organic nanosheet |
PE20210367A1 (en) | 2018-02-02 | 2021-02-26 | Maverix Oncology Inc | GEMCITABIN MONOPHOSPHATE SMALL MOLECULE DRUG CONJUGATES |
US20190351031A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
CN111655710B (en) | 2018-06-29 | 2021-12-21 | 上海长乘医药科技有限公司 | Gemcitabine phosphorus-containing prodrugs |
CN110054659B (en) * | 2019-05-05 | 2020-09-11 | 中国医学科学院医药生物技术研究所 | Method for improving antitumor activity of medicine |
EP3980541A1 (en) | 2019-06-04 | 2022-04-13 | Apterna Limited | Aptamers against transferrin receptor (tfr) |
GB202019692D0 (en) | 2020-12-14 | 2021-01-27 | Apterna Ltd | Aptamer-sirna fusions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4211773A (en) * | 1978-10-02 | 1980-07-08 | Sloan Kettering Institute For Cancer Research | 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides |
EP0184365B1 (en) * | 1984-12-04 | 1993-08-04 | Eli Lilly And Company | Improvements in the treatment of tumors in mammals |
ZA859008B (en) * | 1984-12-04 | 1987-07-29 | Lilly Co Eli | The treatment of tumors in mammals |
FI95384C (en) * | 1989-04-06 | 1996-01-25 | Squibb Bristol Myers Co | Process for the preparation of 3'-deoxy-3'-substituted methyl nucleosides and intermediates used in the process |
CA2079413C (en) * | 1991-09-30 | 2003-09-09 | Masakatsu Kaneko | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use |
US5401838A (en) * | 1992-06-22 | 1995-03-28 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
GB9307043D0 (en) * | 1993-04-05 | 1993-05-26 | Norsk Hydro As | Chemical compounds |
GB9515279D0 (en) * | 1995-07-25 | 1995-09-20 | Norsk Hydro As | Improved therapeutic agents |
-
1998
- 1998-01-23 EP EP98901592A patent/EP0986570B9/en not_active Expired - Lifetime
- 1998-01-23 CA CA002278056A patent/CA2278056C/en not_active Expired - Lifetime
- 1998-01-23 DE DE69812934T patent/DE69812934T2/en not_active Expired - Lifetime
- 1998-01-23 UA UA99084763A patent/UA67736C2/en unknown
- 1998-01-23 KR KR10-1999-7006584A patent/KR100483256B1/en not_active IP Right Cessation
- 1998-01-23 WO PCT/NO1998/000020 patent/WO1998032762A1/en active IP Right Grant
- 1998-01-23 AU AU57827/98A patent/AU720451B2/en not_active Expired
- 1998-01-23 AT AT98901592T patent/ATE236188T1/en active
- 1998-01-23 HU HU0000721A patent/HU224918B1/en not_active IP Right Cessation
- 1998-01-23 PL PL98334856A patent/PL186888B1/en unknown
- 1998-01-23 DK DK98901592T patent/DK0986570T3/en active
- 1998-01-23 NZ NZ336676A patent/NZ336676A/en not_active IP Right Cessation
- 1998-01-23 SK SK1029-99A patent/SK283879B6/en not_active IP Right Cessation
- 1998-01-23 US US09/355,112 patent/US6384019B1/en not_active Expired - Lifetime
- 1998-01-23 JP JP53186298A patent/JP4352115B2/en not_active Expired - Lifetime
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8044034B2 (en) | 2004-06-30 | 2011-10-25 | Centre National De La Recherche Scientifique (C.N.R.S.) | Nanoparticle derivatives of gemcitabine |
EP2055711A1 (en) | 2004-06-30 | 2009-05-06 | Centre National de la Recherche Scientifique | Use of squalenic acid for the formulation of an active principle in nanoparticle state |
WO2006090029A1 (en) | 2004-06-30 | 2006-08-31 | Centre National De La Recherche Scientifique | Gemcitabine derivatives nanoparticles |
US7704972B2 (en) | 2004-06-30 | 2010-04-27 | Centre National De La Recherche Scientifique | Gemcitabine derivatives nanoparticles |
US20100160249A1 (en) * | 2004-06-30 | 2010-06-24 | Centre National De La Recherche Scientifique | Nanoparticle derivatives of gemcitabine |
US20090163564A1 (en) * | 2005-12-28 | 2009-06-25 | Translational Therapeutics, Inc. | Translational Dysfunction Based Therapeutics |
US10472677B2 (en) | 2005-12-28 | 2019-11-12 | Translational Therapeutics, Inc. | Translational dysfunction based therapeutics |
US8497292B2 (en) | 2005-12-28 | 2013-07-30 | Translational Therapeutics, Inc. | Translational dysfunction based therapeutics |
US20090209482A1 (en) * | 2007-09-26 | 2009-08-20 | Mount Sinai School Of Medicine | Azacytidine analogues and uses thereof |
US8158605B2 (en) | 2007-09-26 | 2012-04-17 | Mount Sinai School Of Medicine | Azacytidine analogues and uses thereof |
US8399420B2 (en) | 2007-09-26 | 2013-03-19 | Mount Sanai School of Medicine | Azacytidine analogues and uses thereof |
US20090209477A1 (en) * | 2007-09-26 | 2009-08-20 | Mount Sinai School Of Medicine | Azacytidine analogues and uses thereof |
US20110184053A1 (en) * | 2008-05-16 | 2011-07-28 | Centre National De La Recherche Scientifique | Novel nucleic acid transfer system |
WO2013019945A3 (en) * | 2011-08-02 | 2014-05-08 | Clovis Oncology, Inc.. | Method for selection of chemotherapeutic agents for adenocarcinoma cancer |
WO2016057825A1 (en) * | 2014-10-08 | 2016-04-14 | Epigenetics Pharma Llc | Vitamin e-nucleoside prodrugs |
Also Published As
Publication number | Publication date |
---|---|
JP2001509160A (en) | 2001-07-10 |
CA2278056C (en) | 2006-12-12 |
HUP0000721A2 (en) | 2001-05-28 |
CA2278056A1 (en) | 1998-07-30 |
EP0986570B9 (en) | 2004-01-02 |
HU224918B1 (en) | 2006-04-28 |
EP0986570A1 (en) | 2000-03-22 |
AU5782798A (en) | 1998-08-18 |
US6384019B1 (en) | 2002-05-07 |
WO1998032762A1 (en) | 1998-07-30 |
DK0986570T3 (en) | 2003-07-28 |
UA67736C2 (en) | 2004-07-15 |
HUP0000721A3 (en) | 2002-12-28 |
ATE236188T1 (en) | 2003-04-15 |
NZ336676A (en) | 2000-01-28 |
PL334856A1 (en) | 2000-03-27 |
SK283879B6 (en) | 2004-04-06 |
DE69812934D1 (en) | 2003-05-08 |
AU720451B2 (en) | 2000-06-01 |
KR20000070351A (en) | 2000-11-25 |
PL186888B1 (en) | 2004-03-31 |
SK102999A3 (en) | 2000-05-16 |
DE69812934T2 (en) | 2004-01-29 |
JP4352115B2 (en) | 2009-10-28 |
KR100483256B1 (en) | 2005-04-15 |
EP0986570B1 (en) | 2003-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6384019B1 (en) | Gemcitabine derivatives | |
JP5087052B2 (en) | Improved therapeutic agent | |
US20090203640A1 (en) | Crystalline forms of gemcitabine amide prodrug, compositions and use thereof | |
HU217551B (en) | 6-[(2-hydroxyethyl)-amino-alkyl]-5,11-dioxo-5,6-dihydro-11-h-indeno(1,2-c)isoquinolin derivatives, process for producing them and pharmaceutical compositions containing them | |
RU2194711C2 (en) | Derivatives of hemcytabine | |
US8349834B2 (en) | Dioxolane derivates for the treatment of cancer | |
MXPA99006790A (en) | Gemcitabine derivatives | |
NO318934B1 (en) | gemcitabine | |
JPH08134093A (en) | Carcinostatic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NORSK HYDRO ASA, NORWAY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MYHREN, FINN;BORRETZEN, BERNT;DALEN, ARE;AND OTHERS;REEL/FRAME:010236/0054 Effective date: 19990813 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: CLAVIS PHARMA AS, NORWAY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NORSK HYDRO ASA;REEL/FRAME:017870/0451 Effective date: 20060426 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 12 |
|
SULP | Surcharge for late payment |
Year of fee payment: 11 |